Wave Life Sciences unveils INHBE siRNA for obesity, targets 5 new clinical candidates by 2025

Wave Life Sciences Ltd.

New GalNAc-siRNA program targeting INHBE for metabolic disorders including obesity; expects clinical candidate in 4Q 2024.
INHBE knockdown of 62% in DIO mice led to 16% lower body weight vs control at 5 weeks; visceral fat reduction in 8-week study.
WVE-006 for AATD: dosing in healthy volunteers expected 4Q 2023; proof-of-mechanism data in AATD patients in 2024.
Plans to select five new clinical candidates by year-end 2025, spanning RNA editing (correction and upregulation) and siRNA.
WVE-N531 in DMD: muscle biopsy data show uptake in satellite cells after 3 doses; data from registrational Phase 2 (FORWARD-53) expected 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.